Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN 55902, USA.
Mol Diagn Ther. 2012 Jun 1;16(3):143-50. doi: 10.1007/BF03262202.
Anaplastic lymphoma kinase (ALK) encodes a receptor tyrosine kinase, and ALK gene rearrangement (ALK+) is implicated in the oncogenesis of non-small cell lung carcinomas (NSCLCs), especially adenocarcinomas. The ALK inhibitor crizotinib was approved in August 2011 by the US Food and Drug Administration (FDA) for treating late-stage NSCLCs that are ALK+, with a companion fluorescent in situ hybridization (FISH) test using the Vysis ALK Break Apart FISH Probe Kit. This review covers pertinent issues in ALK testing, including approaches to select target patients for the test, pros and cons of different detection methods, and mechanisms as well as monitoring of acquired crizotinib resistance in ALK+ NSCLCs.
间变性淋巴瘤激酶 (ALK) 编码一种受体酪氨酸激酶，ALK 基因重排 (ALK+) 与非小细胞肺癌 (NSCLC) 的发生有关，尤其是腺癌。ALK 抑制剂克唑替尼于 2011 年 8 月获得美国食品和药物管理局 (FDA) 批准，用于治疗晚期 ALK+ NSCLC，检测方法为使用 Vysis ALK Break Apart FISH Probe Kit 的伴随荧光原位杂交 (FISH) 检测。本文综述了 ALK 检测的相关问题，包括选择目标患者进行检测的方法、不同检测方法的优缺点，以及 ALK+ NSCLC 中获得性克唑替尼耐药的机制和监测。
